{
  "nodes": [
    {
      "id": 1,
      "label": "Query__CQURYPUSER",
      "query": "If quantum computing significantly accelerates drug discovery, what are the ethical implications for pharmaceutical companies’ traditional R&D processes?"
    },
    {
      "id": 2,
      "label": "Affected Parties__CQURYFVLFF"
    },
    {
      "id": 5,
      "label": "Judgement Criteria__CQURYFVLVL"
    },
    {
      "id": 7,
      "label": "Positive Outcomes__CQURYFVLBN"
    },
    {
      "id": 9,
      "label": "Costs and Dangers__CQURYFVLHR"
    },
    {
      "id": 11,
      "label": "Competing Priorities__CQURYFVLTH"
    },
    {
      "id": 13,
      "label": "Ethical Lenses__CQURYFVLNR"
    },
    {
      "id": 15,
      "label": "Incentive Alignment / Misalignment__CQURYFVLIN"
    },
    {
      "id": 17,
      "label": "The Operative Context__CQURYFVLBNDCNTX"
    },
    {
      "id": 18,
      "label": "Drug Discovery Divide__CKGIAPQURY",
      "query": "What would happen to R&D investment patterns in diseases prevalent in low-income populations if quantum computing access were mandated to be shared through a global public consortium?"
    },
    {
      "id": 19,
      "label": "Concrete Instances__CQURYFVLNRDXMPL"
    },
    {
      "id": 20,
      "label": "Drug Development Speed__CGS80PQURY"
    },
    {
      "id": 21,
      "label": "What-If Scenario__CKGIAFHYSC"
    },
    {
      "id": 23,
      "label": "Key Assumptions__CKGIAFHYSS"
    },
    {
      "id": 25,
      "label": "Logical Outcomes__CKGIAFHYCN"
    },
    {
      "id": 27,
      "label": "Branching Possibilities__CKGIAFHYLT"
    },
    {
      "id": 29,
      "label": "Real-World Takeaway__CKGIAFHYMP"
    },
    {
      "id": 31,
      "label": "Baseline Readout__CKGIAFHYCNDMMRY"
    },
    {
      "id": 32,
      "label": "Drug Research Bias__C2JZKPKGIA",
      "query": "What if the primary obstacle to equitable drug discovery isn't computational access but the downstream manufacturing and distribution infrastructure controlled by the same pharmaceutical firms?"
    },
    {
      "id": 33,
      "label": "What-If Scenario__C2JZKFHYSC"
    },
    {
      "id": 35,
      "label": "Key Assumptions__C2JZKFHYSS"
    },
    {
      "id": 37,
      "label": "Logical Outcomes__C2JZKFHYCN"
    },
    {
      "id": 39,
      "label": "Branching Possibilities__C2JZKFHYLT"
    },
    {
      "id": 41,
      "label": "Real-World Takeaway__C2JZKFHYMP"
    },
    {
      "id": 43,
      "label": "Regime Transition__C2JZKFHYMPDTMPR"
    },
    {
      "id": 44,
      "label": "Drug Development Bottleneck__CNY69P2JZK",
      "query": "What if public institutions bypassed pharmaceutical companies entirely by building parallel development and distribution networks—how would that change the ethical weight of quantum-accelerated discovery?"
    },
    {
      "id": 45,
      "label": "The Operative Context__C2JZKFHYSSDCNTX"
    },
    {
      "id": 46,
      "label": "Drug Discovery Bias__CG0X3P2JZK"
    },
    {
      "id": 47,
      "label": "Concrete Instances__C2JZKFHYLTDXMPL"
    },
    {
      "id": 48,
      "label": "Vaccine Production Bottleneck__CO5V7P2JZK",
      "query": "What if the bottleneck in global vaccine access isn't intellectual property but the concentration of skilled personnel needed to operate advanced production facilities?"
    },
    {
      "id": 49,
      "label": "Baseline Readout__C2JZKFHYSCDMMRY"
    },
    {
      "id": 50,
      "label": "Drug Discovery Bias__CXI6KP2JZK",
      "query": "What would happen to drug development priorities if quantum computing made discovery so fast and cheap that the cost of target identification was no longer a constraint on pursuing low-revenue diseases?"
    },
    {
      "id": 51,
      "label": "Baseline Readout__C2JZKFHYCNDMMRY"
    },
    {
      "id": 52,
      "label": "Drug Development Bottleneck__C1LMTP2JZK",
      "query": "What would happen to drug development priorities if public health agencies controlled distribution networks instead of pharmaceutical companies?"
    },
    {
      "id": 53,
      "label": "Clashing Views__C2JZKFHYSSDCNTR"
    },
    {
      "id": 54,
      "label": "Drug Development Bias__CIBE6P2JZK",
      "query": "What if public health agencies could control access to quantum computing platforms for drug discovery—how would that shift the balance of power in determining therapeutic development priorities?"
    },
    {
      "id": 55,
      "label": "Overlooked Angles__C2JZKFHYSCDBLND"
    },
    {
      "id": 56,
      "label": "Drug Company Control__C62DEP2JZK"
    },
    {
      "id": 57,
      "label": "What-If Scenario__CIBE6FHYSC"
    },
    {
      "id": 59,
      "label": "Key Assumptions__CIBE6FHYSS"
    },
    {
      "id": 61,
      "label": "Logical Outcomes__CIBE6FHYCN"
    },
    {
      "id": 63,
      "label": "Branching Possibilities__CIBE6FHYLT"
    },
    {
      "id": 65,
      "label": "Real-World Takeaway__CIBE6FHYMP"
    },
    {
      "id": 67,
      "label": "Concrete Instances__CIBE6FHYMPDXMPL"
    },
    {
      "id": 68,
      "label": "Drug Licensing Deals__CUSJDPIBE6"
    },
    {
      "id": 69,
      "label": "What-If Scenario__CXI6KFHYSC"
    },
    {
      "id": 71,
      "label": "Key Assumptions__CXI6KFHYSS"
    },
    {
      "id": 73,
      "label": "Logical Outcomes__CXI6KFHYCN"
    },
    {
      "id": 75,
      "label": "Branching Possibilities__CXI6KFHYLT"
    },
    {
      "id": 77,
      "label": "Real-World Takeaway__CXI6KFHYMP"
    },
    {
      "id": 79,
      "label": "The Operative Context__CXI6KFHYLTDCNTX"
    },
    {
      "id": 80,
      "label": "Open Vaccine Development__C4SG0PXI6K"
    },
    {
      "id": 81,
      "label": "What-If Scenario__CO5V7FHYSC"
    },
    {
      "id": 83,
      "label": "Key Assumptions__CO5V7FHYSS"
    },
    {
      "id": 85,
      "label": "Logical Outcomes__CO5V7FHYCN"
    },
    {
      "id": 87,
      "label": "Branching Possibilities__CO5V7FHYLT"
    },
    {
      "id": 89,
      "label": "Real-World Takeaway__CO5V7FHYMP"
    },
    {
      "id": 91,
      "label": "Concrete Instances__CO5V7FHYMPDXMPL"
    },
    {
      "id": 92,
      "label": "Vaccine Factory Experts__C02WMPO5V7"
    },
    {
      "id": 93,
      "label": "Concrete Instances__CXI6KFHYSSDXMPL"
    },
    {
      "id": 94,
      "label": "Drug Development Bias__CH8GJPXI6K"
    },
    {
      "id": 95,
      "label": "What-If Scenario__C1LMTFHYSC"
    },
    {
      "id": 97,
      "label": "Key Assumptions__C1LMTFHYSS"
    },
    {
      "id": 99,
      "label": "Logical Outcomes__C1LMTFHYCN"
    },
    {
      "id": 101,
      "label": "Branching Possibilities__C1LMTFHYLT"
    },
    {
      "id": 103,
      "label": "Real-World Takeaway__C1LMTFHYMP"
    },
    {
      "id": 105,
      "label": "Regime Transition__C1LMTFHYMPDTMPR"
    },
    {
      "id": 106,
      "label": "Drug Priority Shifts__CYKB8P1LMT"
    },
    {
      "id": 107,
      "label": "What-If Scenario__CNY69FHYSC"
    },
    {
      "id": 109,
      "label": "Key Assumptions__CNY69FHYSS"
    },
    {
      "id": 111,
      "label": "Logical Outcomes__CNY69FHYCN"
    },
    {
      "id": 113,
      "label": "Branching Possibilities__CNY69FHYLT"
    },
    {
      "id": 115,
      "label": "Real-World Takeaway__CNY69FHYMP"
    },
    {
      "id": 117,
      "label": "Clashing Views__CNY69FHYLTDCNTR"
    },
    {
      "id": 118,
      "label": "Regulatory Gatekeepers__CI449PNY69"
    },
    {
      "id": 119,
      "label": "Overlooked Angles__CO5V7FHYSCDBLND"
    },
    {
      "id": 120,
      "label": "Who Runs The Lab__C8414PO5V7"
    },
    {
      "id": 121,
      "label": "Overlooked Angles__CIBE6FHYSSDBLND"
    },
    {
      "id": 122,
      "label": "Vaccine Production Gap__CQI83PIBE6"
    }
  ],
  "edges": [
    {
      "source": 1,
      "target": 2,
      "relationship": "__anchor__"
    },
    {
      "source": 1,
      "target": 5,
      "relationship": "__anchor__"
    },
    {
      "source": 1,
      "target": 7,
      "relationship": "__anchor__"
    },
    {
      "source": 1,
      "target": 9,
      "relationship": "__anchor__"
    },
    {
      "source": 1,
      "target": 11,
      "relationship": "__anchor__"
    },
    {
      "source": 1,
      "target": 13,
      "relationship": "__anchor__"
    },
    {
      "source": 1,
      "target": 15,
      "relationship": "__anchor__"
    },
    {
      "source": 7,
      "target": 17,
      "relationship": "__anchor__"
    },
    {
      "source": 17,
      "target": 18,
      "relationship": "**Quantum computing will deepen gaps in drug discovery unless global rules ensure fair access because a few firms now control the tools needed for faster innovation.**\n\nA few large pharmaceutical companies control most quantum computing resources for drug development. These firms use proprietary technology to speed up discovery. This limits access for smaller competitors and public institutions. As a result, dominant firms shorten their development timelines. Others find it harder to enter the market. Research focuses more on profitable drugs than public health needs. This pattern grew during the post-genomic era. When key technologies are owned privately, innovation serves profits over need. Without strong regulatory action, new advances will mostly help diseases common in wealthy countries. This widens global health gaps. The same imbalances occurred before with data and drug approval systems. Equal access to quantum computing must be ensured. International rules are needed to share these tools more fairly. Without them, disparities in drug development will grow worse."
    },
    {
      "source": 13,
      "target": 19,
      "relationship": "__anchor__"
    },
    {
      "source": 19,
      "target": 20,
      "relationship": "**Drug safety oversight fails when quantum-accelerated design moves faster than regulators can review, shifting risk to patients because safeguards cannot keep up with speed.**\n\nNew drug design is accelerating fast because of quantum computing. This speed pushes patient safety rules to the breaking point. Clinical trials take time to review risks. But rapid computation shortens that time dramatically. Faster target discovery and toxicity testing now move ahead of oversight systems. Regulators struggle to keep up with these changes. The 2006 TGN1412 trial showed this problem clearly. Preclinical tests missed a deadly immune reaction. The science moved too fast for safety checks. Regulatory agencies like the FDA and EMA depend on slow, step-by-step reviews. They assume discoveries happen at a manageable pace. Quantum-powered drug design breaks that assumption. Companies using private algorithms set standards behind closed doors. The public cannot see how those choices are made. When innovation outpaces ethical oversight, risks shift onto human volunteers. Speed begins to matter more than caution. Safety rules start to fall behind. Commercial power begins to shape research more than patient care. In this setting, ethical standards weaken. Profit and pace take priority over protection."
    },
    {
      "source": 18,
      "target": 21,
      "relationship": "__anchor__"
    },
    {
      "source": 18,
      "target": 23,
      "relationship": "__anchor__"
    },
    {
      "source": 18,
      "target": 25,
      "relationship": "__anchor__"
    },
    {
      "source": 18,
      "target": 27,
      "relationship": "__anchor__"
    },
    {
      "source": 18,
      "target": 29,
      "relationship": "__anchor__"
    },
    {
      "source": 25,
      "target": 31,
      "relationship": "__anchor__"
    },
    {
      "source": 31,
      "target": 32,
      "relationship": "**Public health goals shape drug research when computing access is shared, because funding follows disease burden instead of profit potential.**\n\nWhen private companies control key computing systems, public health goals are pushed aside. Profit motives shape research priorities. This happened with gene study tools in the 2000s. Access limits steered science toward diseases in wealthy countries. Chronic illnesses got funding. Tropical and neglected diseases did not. A global public group could change this pattern. Making quantum computing available this way would shift research spending. Discovery would no longer depend on market value. Health needs could guide science. Removing exclusive control would force funding to follow disease impact, not income potential. Most new drugs developed under this system would aim at illnesses common in poor regions. The focus of drug development would shift."
    },
    {
      "source": 32,
      "target": 33,
      "relationship": "__anchor__"
    },
    {
      "source": 32,
      "target": 35,
      "relationship": "__anchor__"
    },
    {
      "source": 32,
      "target": 37,
      "relationship": "__anchor__"
    },
    {
      "source": 32,
      "target": 39,
      "relationship": "__anchor__"
    },
    {
      "source": 32,
      "target": 41,
      "relationship": "__anchor__"
    },
    {
      "source": 41,
      "target": 43,
      "relationship": "__anchor__"
    },
    {
      "source": 43,
      "target": 44,
      "relationship": "**Equitable drug discovery requires public control over late-stage development and distribution because profit-driven infrastructure bottlenecks block the benefits of faster computational discovery.**\n\nPublic health progress relies on drug development systems controlled by private companies. These systems cover discovery, production, and distribution. Faster computers have improved early research. But this speed does not change which diseases get treated. Companies focus on profitable drugs. Chronic diseases in wealthy countries are more profitable than infectious diseases in poor regions. Manufacturing is concentrated in rich countries. Patents and strict regulations add delays. These barriers block the benefits of faster discovery. Even quantum computing would not fix this. The supply chain and profit motives slow down life-saving treatments. Open access to computing tools is not enough. Public control over late-stage development and distribution is needed. The real bottleneck is not computing power. It is the infrastructure after discovery. This is what limits fair access to new medicines. Equitable drug discovery requires public oversight of these later stages."
    },
    {
      "source": 35,
      "target": 45,
      "relationship": "__anchor__"
    },
    {
      "source": 45,
      "target": 46,
      "relationship": "**Drug discovery benefits the most profitable areas because regulatory and manufacturing control stays with a few firms, so equity requires mandatory sharing of production systems.**\n\nNew technologies speed up drug discovery, but they do not change who benefits. Faster systems have helped cancer drug development because rules reward rare, high-priced treatments. Antibiotic research lags behind, even though resistance is spreading fast. Regulatory programs favor drugs for small patient groups with pricing power. Big firms control both development and supply, limiting broader access. Even if new tools like quantum computing became widely available, production bottlenecks would still block progress. Discovery gains are wasted when the same companies control testing, approval, and supply. Wider access to computing alone does not fix this. Without mandatory sharing of manufacturing capacity and licensing, breakthroughs will keep favoring profitable drugs over global health needs. Fair drug discovery requires shared control over production from start to finish."
    },
    {
      "source": 39,
      "target": 47,
      "relationship": "__anchor__"
    },
    {
      "source": 47,
      "target": 48,
      "relationship": "**Equitable access to vaccines fails because production knowledge is hoarded by a few firms, making manufacturing the bottleneck, not drug discovery.**\n\nPharmaceutical innovation relies on advanced production systems controlled by a few firms. These systems include specialized facilities for making and packaging mRNA vaccines. During the 2021–2022 vaccine shortage, access to these facilities became a major barrier. Even with open data or faster drug design, physical production capacity remained limited. This scarcity is not fixed by better computational tools. The real constraint is the lack of licensed manufacturing sites. Knowledge about how to make the drugs is withheld. International rules on intellectual property protect these trade secrets. As a result, new drug candidates do not lead to wider access. The final products remain unavailable in most regions. The problem is not finding new drugs. It is producing them at scale where they are needed. The same companies that discover drugs also control their production. This control limits who can make and distribute the medicine."
    },
    {
      "source": 33,
      "target": 49,
      "relationship": "__anchor__"
    },
    {
      "source": 49,
      "target": 50,
      "relationship": "**Drug discovery favors profitable treatments over life-saving ones because integrated firms profit more from high-cost therapies, reducing investment in unprofitable but needed medicines.**\n\nWhen companies control both drug discovery and distribution, innovation favors profitable treatments over those with the greatest health impact. This happens because integrated firms can capture more value by focusing on high-priced therapies for wealthier markets. As a result, they invest less in treatments for diseases that affect poorer populations, even if the need is greater. The rise of biologics after 2010 shows this trend clearly. These firms prioritize expensive, low-volume drugs over cheaper, scalable options. Control over the entire supply chain allows them to benefit from market segmentation. This reduces incentives to develop treatments for diseases where people cannot pay. Even if new technologies speed up discovery, the gains go toward treatments that fit current payment systems. Independent manufacturing and distribution networks are missing. The main barrier to fair drug development is therefore the concentration of control over production and supply chains."
    },
    {
      "source": 37,
      "target": 51,
      "relationship": "__anchor__"
    },
    {
      "source": 51,
      "target": 52,
      "relationship": "**The main barrier to fair drug development is corporate control over production and distribution, which directs medicines to profitable markets instead of areas of greatest health need.**\n\nWhen a few powerful companies control key tools for finding new medicines, progress favors drugs that can make the most money. This happened in the 1990s when testing systems focused on blockbuster drugs instead of urgent health needs. The same pattern continues today, even with advanced technologies like quantum computing. The real issue is not who can discover drugs but who controls production, regulation, and distribution. These powers lie with large pharmaceutical firms. They decide which drugs move forward based on profit, not need. Even if discovery becomes widely accessible, final decisions remain in few hands. Access to computing is not the main barrier. The main barrier is control over later stages by profit-driven companies. These companies direct medicines to markets that pay more. Public health needs often lose out."
    },
    {
      "source": 35,
      "target": 53,
      "relationship": "__anchor__"
    },
    {
      "source": 53,
      "target": 54,
      "relationship": "**Drug development favors profitable diseases over urgent health needs because major firms direct innovation based on market returns, not global burden.**\n\nA few large drug companies based in the United States and Europe control most of the global market. They operate under international patent rules that protect their profits. These firms focus on developing drugs for diseases that offer high returns, not high need. They favor treatments for chronic conditions in wealthy countries. These drugs are expensive and profitable. The rules and systems in place reward this kind of innovation. Meanwhile, diseases that affect many people in poorer regions get little research attention. This mismatch is clear in global health data. Even new technologies like quantum-powered discovery will not change this pattern. The real barrier is not production or supply. It is the power of big firms to choose which drugs to develop. They make these choices based on market profits, not patient need. This shapes the entire system from the start."
    },
    {
      "source": 33,
      "target": 55,
      "relationship": "__anchor__"
    },
    {
      "source": 55,
      "target": 56,
      "relationship": "**Equitable access to new drugs fails because production depends on private firms, not because of discovery limits.**\n\nLarge pharmaceutical firms still lead most late-stage drug development and approvals. These firms rely on private supply chains built for expensive, low-volume medicines. Regulatory standards from the FDA and global groups like the ICH favor these controlled systems. They do not support flexible or decentralized manufacturing. Even if new tools like quantum computing speed up drug discovery, access remains limited. Firms control which drugs move into clinical trials and large-scale production. They decide how knowledge and technology are shared. This power is clear in cancer and immune disease research. Many Phase III trials are in these areas, not in infectious diseases. Despite public funding for outbreak prepared and response, progress is slow. The gap between open discovery and fair access persists. This happens because independent, widespread manufacturing capacity does not exist. Current global health rules do not support this independence."
    },
    {
      "source": 54,
      "target": 57,
      "relationship": "__anchor__"
    },
    {
      "source": 54,
      "target": 59,
      "relationship": "__anchor__"
    },
    {
      "source": 54,
      "target": 61,
      "relationship": "__anchor__"
    },
    {
      "source": 54,
      "target": 63,
      "relationship": "__anchor__"
    },
    {
      "source": 54,
      "target": 65,
      "relationship": "__anchor__"
    },
    {
      "source": 65,
      "target": 67,
      "relationship": "__anchor__"
    },
    {
      "source": 67,
      "target": 68,
      "relationship": "**When public health agencies control access to advanced tools and markets, they can shift drug discovery toward global health needs by setting binding research terms that prioritize equity over profit.**\n\nThe Medicines Patent Pool works with the World Health Organization to negotiate access to important medicines. It covers treatments for HIV, hepatitis C, and tuberculosis. This system lets public health agencies link drug pricing to research incentives. Access to large markets and procurement contracts depends on fair pricing. This breaks the link between profit and patient needs. It counters the usual profit-driven model of big drug companies. These companies often avoid low-return diseases in poor countries. The Pool's model uses binding agreements, not charity, to change market signals. It pushes research toward high-impact, neglected diseases. Quantum computing could speed up drug discovery. If public health agencies had controlled access to such tools, they could set early research terms. This would shift power away from private firms. Those firms now focus only on markets protected by strict patent rules. Public agencies instead would guide research based on global health needs. Fairness would become a direct condition of using advanced technology. This would make equity a central rule, not an afterthought. The result would be a major shift in who decides which diseases get attention. Public institutions would gain more control."
    },
    {
      "source": 50,
      "target": 69,
      "relationship": "__anchor__"
    },
    {
      "source": 50,
      "target": 71,
      "relationship": "__anchor__"
    },
    {
      "source": 50,
      "target": 73,
      "relationship": "__anchor__"
    },
    {
      "source": 50,
      "target": 75,
      "relationship": "__anchor__"
    },
    {
      "source": 50,
      "target": 77,
      "relationship": "__anchor__"
    },
    {
      "source": 75,
      "target": 79,
      "relationship": "__anchor__"
    },
    {
      "source": 79,
      "target": 80,
      "relationship": "**Drug development will prioritize public health needs when discovery is separated from profit-driven development, because open infrastructure allows more equitable innovation.**\n\nPublic research and open manufacturing groups can separate early disease target identification from private drug development. This separation means the cost of scaling treatments does not depend on maintaining exclusive rights. During the mRNA vaccine expansion after 2020, shared genetic data and widespread production capacity allowed responses to rare diseases without profit incentives. Modular innovation became possible because technical advances let different groups work in parallel. Intellectual property barriers no longer blocked progress. When discovery is not controlled by a single company, innovations can serve public health needs. Quantum computing could eliminate the cost of finding new drug targets. But faster discovery alone will not shift priorities unless discovery is independent. Only when the infrastructure for finding targets is separate from for-profit development can research focus on widespread health needs instead of market potential."
    },
    {
      "source": 48,
      "target": 81,
      "relationship": "__anchor__"
    },
    {
      "source": 48,
      "target": 83,
      "relationship": "__anchor__"
    },
    {
      "source": 48,
      "target": 85,
      "relationship": "__anchor__"
    },
    {
      "source": 48,
      "target": 87,
      "relationship": "__anchor__"
    },
    {
      "source": 48,
      "target": 89,
      "relationship": "__anchor__"
    },
    {
      "source": 89,
      "target": 91,
      "relationship": "__anchor__"
    },
    {
      "source": 91,
      "target": 92,
      "relationship": "**The lack of trained scientists in low-income countries limits global vaccine access because expertise takes years to build and cannot be transferred through patents alone.**\n\nThe main barrier to making vaccines worldwide is not patent rules. It is the lack of trained scientists and engineers in poorer countries. Even when rich countries waive patent rights, poor countries still cannot produce vaccines. This is because they lack strong science education and training programs. Building labs and sharing blueprints does not help if there are no skilled workers to run them. Training takes years, so the gap cannot be closed quickly. Global health groups focused too much on sharing technology. They ignored the need to train people. Skilled personnel are hard to replace with machines or simple training. The real bottleneck is the unequal spread of advanced education. The ability to operate high-tech facilities lies in human expertise, not legal rights. This expertise is concentrated in rich nations."
    },
    {
      "source": 71,
      "target": 93,
      "relationship": "__anchor__"
    },
    {
      "source": 93,
      "target": 94,
      "relationship": "**Drug development priorities stay focused on profitable markets because companies use efficiency gains to expand pipelines in lucrative areas rather than target unmet needs in low-income regions.**\n\nWhen companies control both drug discovery and distribution, innovation speeds up but does not shift toward diseases that affect the poorest people. Even with faster approval for rare diseases, research funding still avoids high-burden, low-income conditions. This happens because drug development is organized around profit potential. Diseases are treated as pieces chosen to maximize revenue, not health impact. Faster discovery allows more drugs in profitable areas, not riskier ones. Even if quantum computing cuts costs in finding new drug targets, the main factor will still be market fit. Firms with full control will use efficiency to build more drugs for rich markets, not for diseases without strong payers. They will improve what sells, not what is most needed."
    },
    {
      "source": 52,
      "target": 95,
      "relationship": "__anchor__"
    },
    {
      "source": 52,
      "target": 97,
      "relationship": "__anchor__"
    },
    {
      "source": 52,
      "target": 99,
      "relationship": "__anchor__"
    },
    {
      "source": 52,
      "target": 101,
      "relationship": "__anchor__"
    },
    {
      "source": 52,
      "target": 103,
      "relationship": "__anchor__"
    },
    {
      "source": 103,
      "target": 105,
      "relationship": "__anchor__"
    },
    {
      "source": 105,
      "target": 106,
      "relationship": "**Drug development targets severe diseases in poor regions when health agencies control distribution and pricing, but only if that control lasts.**\n\nWhen public health agencies take control from private firms, they use health burden data to decide which drugs to prioritize. This replaces profit goals with measures of how many lives could be saved. The World Health Organization’s list of essential medicines shapes what countries buy. This influences drug makers early in development. Developers then focus on serious diseases in poor regions. GAVI’s vaccine funding changed development paths in the 2010s. But these changes only last if public agencies keep control. Control fades when emergency funds end or politicians lose interest. Antibiotic innovation dropped after 2015 despite WHO warnings. So priorities shift toward urgent health needs only if public agencies keep power over access and pricing. That power must be strong and lasting."
    },
    {
      "source": 44,
      "target": 107,
      "relationship": "__anchor__"
    },
    {
      "source": 44,
      "target": 109,
      "relationship": "__anchor__"
    },
    {
      "source": 44,
      "target": 111,
      "relationship": "__anchor__"
    },
    {
      "source": 44,
      "target": 113,
      "relationship": "__anchor__"
    },
    {
      "source": 44,
      "target": 115,
      "relationship": "__anchor__"
    },
    {
      "source": 113,
      "target": 117,
      "relationship": "__anchor__"
    },
    {
      "source": 117,
      "target": 118,
      "relationship": "**Global drug development follows rich-country rules because regulatory standards from the U.S. and Europe act as a gate that all therapies must pass, regardless of where they are developed or who needs them.**\n\nNational regulators in rich countries shape global drug approval. The U.S. and Europe set strict safety and efficacy rules. These rules steer where drug research goes. Even public and global health programs must follow them. Trials are designed for wealthy populations. This leaves out treatments needed in poor regions. Drugs must meet Western standards to move forward. Discovery funding does not change this path. Patent deals or price cuts do not fix it. The real barrier is the system of approval. It controls which drugs get made. It does so no matter who funds the science."
    },
    {
      "source": 81,
      "target": 119,
      "relationship": "__anchor__"
    },
    {
      "source": 119,
      "target": 120,
      "relationship": "**Drug discovery directions depend on where skilled researchers are, not just who owns the technology, because expertise determines how tools are used.**\n\nPublic control of advanced computing may aim to shift drug research toward high-burden diseases. The idea is that better access to technology drives more equitable results. But past efforts show access alone is not enough. Sub-Saharan Africa and Southeast Asia still lack genomics research capacity. This is true even after decades of technology transfers by major global health groups. Most AI and high-performance computing projects in medicine rely on experts. These experts are mostly in wealthy countries. Programs like H3Africa prove that without training local talent, tools alone change little. Research priorities stay fixed on the needs of where the experts are. Therefore, giving nations access to quantum computing will not redirect drug discovery. Skilled personnel are the limiting factor. Without them, ownership of technology does not lead to local health solutions."
    },
    {
      "source": 59,
      "target": 121,
      "relationship": "__anchor__"
    },
    {
      "source": 121,
      "target": 122,
      "relationship": "**Equitable access to vaccines fails because open research does not override the lack of global authority to mandate technology transfer and align production incentives.**\n\nPublic research groups and open alliances cannot force data sharing or coordinate global manufacturing. This was clear during the 2020–2022 pandemic. Many countries struggled to access tests and treatments. Most mRNA vaccines were made by a few large firms. These firms kept control despite public funding for early science. The World Health Organization started a technology hub to spread know-how. But it moved slowly. Firms did not share technology. had different rules. Decentralized research networks could not fix this. Open data alone did not ensure fair access. Why? Global health bodies lack power to force cooperation. They cannot compel technology sharing. They cannot align profit motives across countries. Discovery may be open. But development is concentrated. Without strong international rules, this gap will persist."
    }
  ],
  "query": "If quantum computing significantly accelerates drug discovery, what are the ethical implications for pharmaceutical companies’ traditional R&D processes?"
}